RBC Capital Defends Legend (LEGN) For Second Day in a Row As Stock Continues to Push Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/3/2026
- Wall Street ends lower as Middle East tensions escalate
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Broadcom's sales and AI chip forecast comes in below expectations, shares tumble
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Oil gains as Middle East hostilities flare
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
- Navitas showcases 800V power delivery board at NVIDIA MGX ecosystem event
- Inotiv files for bankruptcy with $65 million financing commitment
- Alphabet plans $80 billion equity raise to fund AI infrastructure expansion, Berkshire Hathaway to invest $10 billion
- Alphabet plans $80 billion raise for AI, backed by Buffett’s Berkshire
- After-Hours Stock Movers: AVGO, CRWD, FIVE, AI, TLYS, NTSK,
- After-Hours Stock Movers: PANW, CRWD, ZS, GTLB, ULTA
- After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP
- After-Hours Stock Movers: DELL, MDB, AEO, NTAP, GAP, S, ADSK
- After-Hours Stock Movers: CRM, MRVL, SNOW, HPQ, DDOG, MDB, P, SNPS, BRZE, NCNO
Legend Biotech Corp. (LEGN) PT Lowered to $48 at UBS
December 8, 2025 9:08 AM ESTUBS analyst Ashwani Verma lowered the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $48.00 (from $54.00) while maintaining a Buy rating.... More
RBC Capital on Legend Biotech Corp. (LEGN): 'We Would Be Buyers'
December 8, 2025 7:49 AM ESTRBC Capital analyst Leonid Timashev reiterated an Outperform rating and $74.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst commented: "With Latest Data Cuts, We Still Think Carvykti Looks To Have Superior Efficacy; Following updates at ASH this weekend, we... More
Legend Biotech reports 50-month survival data for CARVYKTI in myeloma
December 8, 2025 2:54 AM ESTLegend Biotech Corporation (NASDAQ: LEGN) announced clinical data showing a median progression-free survival of 50.4 months for triple-class exposed multiple myeloma patients who received three prior lines of therapy and were treated with CARVYKTI® (ciltacabtagene autoleucel) in the CARTITUDE-1 and CARTITUDE-4 studies.
The data was presented at the 67th American Society of Hematology Annual... More
